[Analysis of the efficacy and influencing factors of nilotinib or dasatinib as second- or third-line treatment in patients with chronic myeloid leukemia in the chronic phase and accelerated phase].
Ting Yuan(Goethe University Frankfurt), Qian Jiang(Peking University), Xiao‐Jun Huang(Peking University), Yuni Lai, Y Z Qin(Beijing Academy of Agricultural and Forestry Sciences), Hongxia Shi(Xinjiang Medical University), Yue Hou
Cited by 3
Related Papers
Small molecules in targeted cancer therapy: advances, challenges, and future perspectives
|Signal Transduction and Targeted Therapy|2021|1.7k
Manganese Increases the Sensitivity of the cGAS-STING Pathway for Double-Stranded DNA and Is Required for the Host Defense against DNA Viruses
|Immunity|2018|809
New insights into oxidative stress and inflammation during diabetes mellitus-accelerated atherosclerosis
|Redox Biology|2018|753
Targeted tumour theranostics in mice via carbon quantum dots structurally mimicking large amino acids
|Nature Biomedical Engineering|2020|409
MBD2 serves as a viable target against pulmonary fibrosis by inhibiting macrophage M2 program
|Science Advances|2021|233